Radiology Registry on Pancreatic Malignancies
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- IRCCS San Raffaele
- Enrollment
- 1,300
- Locations
- 1
- Primary Endpoint
- Progression- free survival
Study Overview
Brief Summary
The purpose of this study is to collect all radiological data which evaluated with clinical data may help assess malignancy and prognosis of pancreatic disease.This registry aims to collect retrospective data from 2014 and prospective data until 2027 with a maximum follow-up of 3 years per patient.
Detailed Description
Single center, observational (retrospective and prospective) will collect all available parameters to assess the clinical outcome of the patients (progression free survival (PFS), overall survival (OS), local progression free survival LTPFS), response to treatment) with pancreatic neoplasms presenting to San Raffaele. Patient assignment to a given diagnostic and/or therapeutic procedure is not related to random assignment methods but is part of the ordinary therapeutic strategy planned for each patient on an individual basis and after multidisciplinary discussion.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Other
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •≥18 years of age
- •Patients with suspect (planned for investigation) or diagnosed pancreatic cancer at any stage.
- •able and willing to sign informed consent
Exclusion Criteria
- •Patients with non-primary pancreatic disease
Outcomes
Primary Outcomes
Progression- free survival
Time Frame: From date of intervention until the date of first documented progression, up to a maximum of 3 years
Time from start of observation to disease progression
Local progression free survival
Time Frame: From date of intervention until the date of first documented local progression assessed up to a maximum of 3 years
Time between (start of) a locoregional treatment and local disease progression
Secondary Outcomes
- Overall Survival(From date of treatment until the date of death from any cause assessed up to 3 years)
Investigators
Francesco De Cobelli
Head of Radiology
IRCCS San Raffaele